[
  {
    "ts": null,
    "headline": "1 Blue-Chip Dividend Stock That Still Has Room to Run",
    "summary": "This pharmaceutical leaders offers a combination of growth, income, and innovation.",
    "url": "https://finnhub.io/api/news?id=3d527a3af3a34c81224dbf943b6830e2731e3f67e9754e369ffb0edbb2957d8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754004602,
      "headline": "1 Blue-Chip Dividend Stock That Still Has Room to Run",
      "id": 136160994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "This pharmaceutical leaders offers a combination of growth, income, and innovation.",
      "url": "https://finnhub.io/api/news?id=3d527a3af3a34c81224dbf943b6830e2731e3f67e9754e369ffb0edbb2957d8e"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results",
    "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerabi",
    "url": "https://finnhub.io/api/news?id=04c8a3ea69adaad91fdff3a839b8caa7df4c5a1f956904e340157c4490f0c781",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992300,
      "headline": "OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results",
      "id": 136160996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerabi",
      "url": "https://finnhub.io/api/news?id=04c8a3ea69adaad91fdff3a839b8caa7df4c5a1f956904e340157c4490f0c781"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
    "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
    "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986479,
      "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
      "id": 136160874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
      "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
    "summary": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
    "url": "https://finnhub.io/api/news?id=c2d7a9ce3b26e01311ba0f78076a85091b7a82af8a7d2918853887f38d08db8e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753977060,
      "headline": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
      "id": 136168496,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
      "url": "https://finnhub.io/api/news?id=c2d7a9ce3b26e01311ba0f78076a85091b7a82af8a7d2918853887f38d08db8e"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Merck share losses lead Dow's 231-point fall",
    "summary": "UnitedHealth, Merck share losses lead Dow's 231-point fall",
    "url": "https://finnhub.io/api/news?id=aa17fe5c1d727123fd0309e24cd4d613ba495a7fa13715dd4fa12bb56e214bfa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970820,
      "headline": "UnitedHealth, Merck share losses lead Dow's 231-point fall",
      "id": 136168497,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Merck share losses lead Dow's 231-point fall",
      "url": "https://finnhub.io/api/news?id=aa17fe5c1d727123fd0309e24cd4d613ba495a7fa13715dd4fa12bb56e214bfa"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 113-point drop led by losses for shares of UnitedHealth, Nike",
    "summary": "Dow's 113-point drop led by losses for shares of UnitedHealth, Nike",
    "url": "https://finnhub.io/api/news?id=cfdc1345086464522095bbc70c2d1f9fd26f9928512d66b235bb358b6a3c51d5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753960380,
      "headline": "Dow's 113-point drop led by losses for shares of UnitedHealth, Nike",
      "id": 136168498,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 113-point drop led by losses for shares of UnitedHealth, Nike",
      "url": "https://finnhub.io/api/news?id=cfdc1345086464522095bbc70c2d1f9fd26f9928512d66b235bb358b6a3c51d5"
    }
  },
  {
    "ts": null,
    "headline": "Chicken Pox Market Analysis and Forecast 2025-2035 | Varicella Vaccine Demand Soars as Global Health Initiatives Expand",
    "summary": "The global chicken pox market is experiencing significant growth driven by the widespread prevalence of the varicella-zoster virus, low vaccination rates in certain regions, and increasing awareness about vaccination benefits. Despite regulatory challenges and seasonality affecting supply and demand, initiatives such as government immunization mandates and improved vaccination technology are propelling the market forward. Live attenuated and combination vaccines are gaining traction due to their",
    "url": "https://finnhub.io/api/news?id=1678645a19b6fcaff3218b75d5928df6caa017e4d364c1aa18b1a59926135ada",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753958820,
      "headline": "Chicken Pox Market Analysis and Forecast 2025-2035 | Varicella Vaccine Demand Soars as Global Health Initiatives Expand",
      "id": 136151855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global chicken pox market is experiencing significant growth driven by the widespread prevalence of the varicella-zoster virus, low vaccination rates in certain regions, and increasing awareness about vaccination benefits. Despite regulatory challenges and seasonality affecting supply and demand, initiatives such as government immunization mandates and improved vaccination technology are propelling the market forward. Live attenuated and combination vaccines are gaining traction due to their",
      "url": "https://finnhub.io/api/news?id=1678645a19b6fcaff3218b75d5928df6caa017e4d364c1aa18b1a59926135ada"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
    "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
    "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954980,
      "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
      "id": 136151856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
      "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e"
    }
  },
  {
    "ts": null,
    "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
    "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
    "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954260,
      "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
      "id": 136151783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
      "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02"
    }
  },
  {
    "ts": null,
    "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
    "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
    "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954020,
      "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
      "id": 136151804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
      "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, Oppenheimer analyst Ken Wong noted that Outperform-rated Veeva announced that Merck & Co., Inc. (NYSE:MRK) has committed to Vault CRM. The announcement marks Veeva’s sixth enterprise pharma Vault CRM commitment. The firm […]",
    "url": "https://finnhub.io/api/news?id=4f2f2fb5bf99f4cd99645d694c99237a8198fd11aa976701b737b8fe740369e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753934364,
      "headline": "Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM",
      "id": 136148916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, Oppenheimer analyst Ken Wong noted that Outperform-rated Veeva announced that Merck & Co., Inc. (NYSE:MRK) has committed to Vault CRM. The announcement marks Veeva’s sixth enterprise pharma Vault CRM commitment. The firm […]",
      "url": "https://finnhub.io/api/news?id=4f2f2fb5bf99f4cd99645d694c99237a8198fd11aa976701b737b8fe740369e9"
    }
  }
]